BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Magan AA, Khalil AA, Ahmed MH. Terlipressin and hepatorenal syndrome: What is important for nephrologists and hepatologists. World J Gastroenterol 2010; 16(41): 5139-5147 [PMID: 21049548 DOI: 10.3748/wjg.v16.i41.5139]
URL: https://www.wjgnet.com/1007-9327/full/v16/i41/5139.htm
Number Citing Articles
1
Évangéline Pillebout. Syndrome hépatorénalNéphrologie & Thérapeutique 2014; 10(1): 61 doi: 10.1016/j.nephro.2013.11.005
2
Shuzhen Yu, Yongqing Guo, Weiwei Zhang, Lina Zheng, Junming Ren, Jianmin Jin, Baofeng Yu, Yu Zhang, Hao Wang, Yuhong Zhang. Effects of propofol pretreatment on myocardial cell apoptosis and SERCA2 expression in rats with hepatic ischemia/reperfusionBrazilian Journal of Anesthesiology (English Edition) 2018; 68(6): 591 doi: 10.1016/j.bjane.2018.07.001
3
Mohamed H. Ahmed, Salma Barakat, Ahmed O. Almobarak. The association between renal stone disease and cholesterol gallstones: the easy to believe and not hard to retrieve theory of the metabolic syndromeRenal Failure 2014; 36(6): 957 doi: 10.3109/0886022X.2014.900424
4
Garmen A. Woo, Christopher O'Brien. Long-term Management of Alcoholic Liver DiseaseClinics in Liver Disease 2012; 16(4): 763 doi: 10.1016/j.cld.2012.08.007
5
Naina Shah, Fatma E. Mohamed, Maria Jover‐Cobos, Jane Macnaughtan, Nathan Davies, Richard Moreau, Valerie Paradis, Kevin Moore, Raj Mookerjee, Rajiv Jalan. Increased renal expression and urinary excretion of TLR4 in acute kidney injury associated with cirrhosisLiver International 2013; 33(3): 398 doi: 10.1111/liv.12047
6
Christopher M Moore, David H Van Thiel. Cirrhotic ascites review: Pathophysiology, diagnosis and managementWorld Journal of Hepatology 2013; 5(5): 251-263 doi: 10.4254/wjh.v5.i5.251
7
Basilio Fimiani, Domenico Della Guardia, Claudio Puoti, Giuseppe D' Adamo, Olimpia Cioffi, Anna Pagano, Maria Rosaria Tagliamonte, Antonio Izzi. The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: A multicentric studyEuropean Journal of Internal Medicine 2011; 22(6): 587 doi: 10.1016/j.ejim.2011.06.013
8
E. Pillebout. Syndrome hépatorénalEMC - Néphrologie 2006; 1(1): 1 doi: 10.1016/S1762-0945(11)58254-3
9
Shuzhen Yu, Yongqing Guo, Weiwei Zhang, Lina Zheng, Junming Ren, Jianmin Jin, Baofeng Yu, Yu Zhang, Hao Wang, Yuhong Zhang. Efeitos do pré‐tratamento com propofol sobre a apoptose de células miocárdicas e expressão de SERCA2 em ratos com isquemia/reperfusão hepáticaBrazilian Journal of Anesthesiology 2018; 68(6): 591 doi: 10.1016/j.bjan.2018.06.003
10
Wisit Kaewput, Charat Thongprayoon, Carissa Y Dumancas, Swetha R Kanduri, Karthik Kovvuru, Chalermrat Kaewput, Pattharawin Pattharanitima, Tananchai Petnak, Ploypin Lertjitbanjong, Boonphiphop Boonpheng, Karn Wijarnpreecha, Jose L Zabala Genovez, Saraschandra Vallabhajosyula, Caroline C Jadlowiec, Fawad Qureshi, Wisit Cheungpasitporn. In-hospital mortality of hepatorenal syndrome in the United States: Nationwide inpatient sampleWorld Journal of Gastroenterology 2021; 27(45): 7831-7843 doi: 10.3748/wjg.v27.i45.7831
11
Taka-aki Koshimizu, Kazuaki Nakamura, Nobuaki Egashira, Masami Hiroyama, Hiroshi Nonoguchi, Akito Tanoue. Vasopressin V1a and V1b Receptors: From Molecules to Physiological SystemsPhysiological Reviews 2012; 92(4): 1813 doi: 10.1152/physrev.00035.2011
12
Eric K. Judd, Shikha Mehta, Ashita J. Tolwani. Clinical Decisions in Nephrology, Hypertension and Kidney Transplantation2013; : 199 doi: 10.1007/978-1-4614-4454-1_21